LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Curaleaf Holdings, Inc. (“Curaleaf” or the “Company”) (OTC: CURLF) investors concerning the Company and its officers’ possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com.
On July 22, 2019, the Company received a warning letter from the FDA, which revealed that the Company was selling unapproved new and misbranded drugs for both human and animal consumption, as well as marketing CBD products improperly as dietary supplements.
On this news, shares of Curaleaf fell $0.58 per share, or over 7%, to close at $7.40 on July 23, 2019, thereby injuring investors.
If you purchased Curaleaf securities, have information, or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067 at 310-201-9150, Toll-Free at 888-773-9224, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number, and the number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
